TESAMORELIN.XYZ explains a lab-made copy of the hormone that tells the pituitary to release growth hormone. We sell nothing here.
Home›Rules & Safety

Legal Status and Safety

Rules & Safety
The short version:
Tesamorelin is licensed in the US and Canada for one narrow use. Europe has never approved it, and research-grade material is not intended for people.

Some websites present tesamorelin as a general fat burner or anti-ageing shot. Regulators see it very differently: a medicine for one group of patients in North America, and an unapproved substance in Europe.

Where It Stands

  • United States: a prescription medicine, sold as Egrifta SV and Egrifta WR, to reduce excess abdominal fat in adults with HIV and lipodystrophy. The label states that it is not for weight loss.
  • Canada: approved by Health Canada in 2014 for the same group of patients.
  • European Union: no authorisation. The only application, for Egrifta, was withdrawn in 2012 after the experts reviewing it judged that the benefits did not outweigh the risks.
  • United Kingdom: no tesamorelin product is licensed by the MHRA.
  • Sport: growth hormone-releasing factors are on the World Anti-Doping Agency's list of substances banned at all times.

Common Side Effects

In the trials, the most frequent complaints were redness, itching or pain where the injection went in, joint pain, pain in the arms or legs, muscle aches and swelling of the hands or feet. Most of these are typical of higher growth hormone levels and tend to ease over time.

Warnings on the Label

  • Blood sugar: it can make the body handle glucose less well, so the label calls for regular checks, especially in people with diabetes.
  • IGF-1: levels rise, and the label advises monitoring because high IGF-1 over long periods is a concern.
  • Fluid retention: swelling and joint or nerve discomfort, such as carpal tunnel symptoms, can occur.
  • Cancer: it should not be used by people with active cancer, because growth hormone may encourage tumour growth.
  • Allergic reactions: rashes and, rarely, more serious reactions have been reported.

Who Should Not Use It

The US label rules it out in pregnancy and in people whose pituitary gland has been damaged by surgery, a tumour or radiation. It is also not meant for people who are acutely and critically ill.

Open Questions

  • Heart outcomes: no trial has shown that it prevents heart disease.
  • Long-term safety: controlled data stop at around one year.
  • People without HIV: there are very few studies outside this group.
  • Research powders: they are not made to medicine standards and come without dosing guidance or a patient leaflet.

To Sum Up

Tesamorelin is a genuine, approved medicine, but only for a specific group of patients and only in North America. In Europe and the UK it has no licence. Anyone considering it for health reasons should see a doctor first.

This page is general information, not legal advice.